Monoclonal Antibodies in the Treatment of B-Cell Malignancies
Authors: K. John Morrow
Journal: Annals of Internal Medicine (1988)

Editorials15 August 1988Monoclonal Antibodies in the Treatment of B-Cell MalignanciesK. John Morrow Jr.K. John Morrow Jr.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-4-263 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMonoclonal antibodies hold great promise for cancer treatment, because they can act specifically against cancer cells, an advantage unavailable in any other therapy. However many difficulties must be overcome before this therapy can be applied generally.One of the most substantial obstacles to the development of cancer immunotherapy with monoclonal antibodies is the fact that no cancer-specific antigens have been shown; the current dogma proposes "tumor-associated" antigens that may also be present in fetal tissue or other normal cellular elements (1). Two approaches to the lack of satisfactory antigenic sites have been attempted with B-cell malignancies. First, efforts have been...References1. Marx J. Monoclonal antibodies in cancer. Science. 1982;216:283-5. CrossrefMedlineGoogle Scholar2. Foon K. Advances in cancer: monoclonal antibody therapy of hematologic malignancies. NJ Med. 1987;84:269-74. MedlineGoogle Scholar3. Dillman R, Shawler D, and Sobol R. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood. 1982;59:1036-45. CrossrefMedlineGoogle Scholar4. Foon K, Schroff R, and Bunn P. Effect of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood. 64:1085-93. CrossrefMedlineGoogle Scholar5. Meeker T, Lowder J, and Maloney D. A clinical trial of anti-idiotype therapy for B-cell malignancy. Blood. 1985;65:1349-63. CrossrefMedlineGoogle Scholar6. Miller R, Maloney D, Warnke R, and Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517-22. CrossrefMedlineGoogle Scholar7. Lowder J, Meeker T, and Campbell M. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood. 1987;69:199-210. CrossrefMedlineGoogle Scholar8. Rankin E, Hekman A, Somers R, and ten Bokkel Huinink W. Treatment of two patients with B cell lymphoma with monoclonal anti-idiotype antibodies. Blood. 1985;65:1373-81. CrossrefMedlineGoogle Scholar9. Hamblin T, Abdul-Ahad A, Gordon J, Stevenson F, and Stevenson G. Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces. Br J Cancer 1980;42:495-502. CrossrefMedlineGoogle Scholar10. Gordon J, Abdul-Ahad A, Hamblin T, Stevenson F, and Stevenson G. Mechanisms of tumor cell escape encountered in treating lymphocytic leukaemia with anti-idiotypic antibody. Br J Cancer. 1984;49:547-57. CrossrefMedlineGoogle Scholar11. Miller R, Maloney D, McKillop J, and Levy R. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood. 1981;58:78-86. CrossrefMedlineGoogle Scholar12. Nadler L, Takvorian T, and Botnick L. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet. 1984;2:427-43. CrossrefMedlineGoogle Scholar13. Miller R, Oseroff A, Stratte P, and Levy R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood. 1983;62:988-95. CrossrefMedlineGoogle Scholar14. Ball E, Bernier G, Cornwell G, McIntyre O, O'Donnell J, and Fanger M. Monoclonal antibodies to myeloid differentiation antigens: in vivo studies of three patients with acute myelogenous leukemia. Blood. 1983;62:1203-10. MedlineGoogle Scholar15. Hamblin T, Cattan A, and Glennie M. Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody. Blood. 1987;69:790-7. CrossrefMedlineGoogle Scholar16. Cleary M, Meeker T, and Levy S. Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell. 1986;44:97-106. CrossrefMedlineGoogle Scholar17. Glennie M, McBride H, Stirpe F, Thorpe P, Worth A, and Stevenson G. Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of anti-idiotypic antibody and saporin. J Exp Med. 1987;166:43-62. CrossrefMedlineGoogle Scholar18. Vaickus L and Levy R. Antiproliferative monoclonal antibodies: detection and initial characterization. J Immunol. 1985;135:1987-97. CrossrefMedlineGoogle Scholar19. Ritz J, Pesando J, and Sallan S. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood. 1981;58:141-52. CrossrefMedlineGoogle Scholar20. DeFabritiis P, Bregni M, and Lipton J Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydro-peroxycyclophosphamide in combination with monoclonal antibodies and complement. Blood. 1985;65:1064-70. CrossrefMedlineGoogle Scholar21. Meeker T, Lowder J, Cleary M, Stewart S, Warnke R, Sklar J, and Levy R. Emergence of idiotype variants during treatment of B-cell lymphoma with antiidiotypic antibodies. N Engl J Med. 1985;312:1658-65. CrossrefMedlineGoogle Scholar22. DePinho R, Feldman L, and Scharff M. Tailor-made monoclonal antibodies. Ann Intern Med. 1986;104:225-33. LinkGoogle Scholar23. Spira G, Bargellesi A, Pollack R, Aguila H, and Scharff M. The generation of better monoclonal antibodies through somatic mutation. In: Springer TA, ed. Hybridoma Technology in the Biosciences and Medicine. Plenum: New York; 1985:74-86. CrossrefGoogle Scholar24. Morrison S, Johnson M, Herzenberg L, and Oi V. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA. 1984;81:6851-5. CrossrefMedlineGoogle Scholar25. Stevenson F, Wrightham M, and Glennie M. Antibodies to shared idiotypes as agents for analysis and therapy for human B cell tumors. Blood. 1986;68:430-6. CrossrefMedlineGoogle Scholar26. Anderson-Berg W, Squire R, and Strand M. Specific radioimmunotherapy using 90Y-labeled monoclonal antibody in erythroleukemic mice. Cancer Res. 1987;47:1905-12. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: K. John MorrowJr.Affiliations: Texas Tech University Health Sciences Center Lubbock, Texas PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCytokines in the Pathogenesis and Management of Non-Hodgkin’s LymphomasTherapy of the plasma cell tumors 15 August 1988Volume 109, Issue 4Page: 263-265KeywordsAntigensB cellsCancer immunotherapyCancer treatmentCellsFetusesMonoclonal antibodies ePublished: 1 December 2008 Issue Published: 15 August 1988 PDF downloadLoading ...